Alamar Biosciences (ALMR) vs Axogen (AXGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axogen is the larger company by market cap ($2.12 billion vs $1.75 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMR | AXGN |
|---|---|---|
| Share price | $25.27 | $36.13 |
| Market cap | $1.75B | $2.12B |
| 1-day change | -2.47% | -0.14% |
| YTD return | — | +10.39% |
| 1-year return | — | +120.04% |
| 5-year return | — | +165.64% |
| Forward P/E | — | 52.51 |
| EPS (TTM) | $-1.20 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $225.21M |
| Revenue growth (YoY) | — | +20.21% |
| Net income (latest FY) | — | $-15.70M |
| Gross margin | — | 74.31% |
| Operating margin | — | -3.49% |
| Net margin | — | -6.97% |
| 52-week high | $39.61 | $52.91 |
| 52-week low | $18.85 | $15.27 |
| Distance from 52-week high | -36.20% | -31.71% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +40.09% | +48.96% |
| Average volume | 411.15K | 1.22M |
| Shares outstanding | 69.39M | 58.67M |
| Employees | 286 | 622 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Alamar Biosciences in Industrials and Axogen in Health Care.
About Alamar Biosciences
ALMR stock →Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers.
Industrials · Biotechnology: Laboratory Analytical Instruments · 286 employees
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
ALMR vs AXGN FAQ
Which is bigger, Alamar Biosciences or Axogen?
Axogen (AXGN) is larger, with a market capitalization of $2.12B compared with $1.75B for Alamar Biosciences (ALMR).
Are Alamar Biosciences and Axogen in the same industry?
No. Alamar Biosciences is in the Industrials sector, while Axogen is in Health Care.